COMy 2020 | New modalities of immunotherapy for myeloma
Sagar Lonial
• 30 Sep 2020
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the new modalities of immunotherapy for myeloma. For example, belantamab mafodotin is an antibody-drug conjugate that targets B-cell maturation antigens (BCMA). There are also multiple CAR-T products that could soon become the first to be approved for myeloma, such as ide-cel also known as bb2121. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Advisory board: Celgene, Takeda, Janssen, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Abbvie, Kayropharm
Research support: Celgene, BMS, Janssen, Takeda
Member of the board of directors TG therapeutics
